Semaglutide for Health & Longevity

Created on 10/31/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Semaglutide is a prescription medication for diabetes and weight loss, a weekly injection or daily tablet copying an appetite-controlling gut hormone. In adults with excess weight, diabetes, or heart or kidney disease, strong evidence shows weight loss, fewer heart attacks and strokes, slower kidney decline and longer survival. In lean, healthy adults, benefit is uncertain. Digestive side effects are common, some weight lost is muscle, and benefits fade after stopping. (Full Review)

Protocol

Weight and cardiovascular protocol (Wegovy injection)
2.4 mg (or 1.7 mg) weekly
0.25 mg weekly for 4 weeks, then 0.5, 1 and 1.7 mg in 4-week steps; up to 7.2 mg for further weight loss; any time of day, same weekday
Oral weight protocol (Wegovy tablets)
25 mg daily
1.5 mg daily for 30 days, then 4 mg and 9 mg; on waking, empty stomach, 30 minutes before food or drink
Lower-dose longevity approach (no outcome trials)
0.5–1 mg weekly
Diabetes doses; Peter Attia notes the mouse lifespan dose approximated human exposure between diabetes and weight-loss doses
Time to effect
Weight loss
12–16 months
Most weight loss accrues over this period, as in STEP 1
Cardiovascular benefit
Years
Emerged over years of follow-up in SELECT
Appetite
Days
Falls within days of starting

Benefits

Contraindications
  • Personal or family history of medullary thyroid carcinoma, or MEN 2
  • Prior serious hypersensitivity, including anaphylaxis, to semaglutide or its inactive ingredients
  • Pregnancy, or pregnancy planned within 2 months
  • Breastfeeding while using semaglutide tablets
  • Severe gastroparesis
  • Confirmed NAION during treatment
  • Type 1 diabetes (use has not been evaluated)
  • Prior pancreatitis (inferred; no trial data)
  • Underweight (body-mass index below 18.5) or active eating disorder (no human data)
Key Interactions
  • Insulin and sulfonylureas (glipizide, glimepiride): higher risk of hypoglycemia, including severe episodes
  • Levothyroxine with oral semaglutide: higher thyroxine exposure
  • Other tablets taken with oral semaglutide: lower semaglutide exposure
  • Lisinopril, warfarin, digoxin and metformin with oral semaglutide: higher metformin exposure, judged not clinically relevant
  • Rosuvastatin and furosemide with oral semaglutide: higher exposure, judged not clinically relevant
  • Alectinib (a lung-cancer drug): lower alectinib exposure
  • Lithium (a mood stabilizer): lithium levels rose to toxicity
  • Blood-pressure-lowering drugs (amlodipine): more hypotension
  • Other GLP-1 receptor agonists or semaglutide products (liraglutide, tirzepatide): co-use not recommended
Theoretical (inferred from mechanism)
  • Loperamide (over the counter) and opioid-containing cough or antidiarrheal products (codeine): may worsen constipation or contribute to stalled bowel movement
  • NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen, over the counter): may raise acute kidney injury risk during vomiting or diarrhea
  • Glucose-lowering supplements (berberine): may increase hypoglycemia in people also taking insulin or sulfonylureas
  • Fiber supplements (psyllium): may worsen nausea and bloating
  • Blood-pressure-lowering supplements (beetroot nitrate): may cause dizziness or low blood pressure
  • Alcohol: additive hypoglycemia in insulin users; possible additive pancreatitis risk
  • Very-low-calorie diets or prolonged fasting: may accelerate lean-mass loss and gallstone formation

Risk & Side Effects

  • High: Gastrointestinal adverse events; gallbladder disease; weight and metabolic rebound after stopping; fatigue, dizziness and headache
  • Medium: Lean mass loss; NAION; low blood glucose with insulin or sulfonylureas; hair loss; skin sensitivity at high dose; higher resting heart rate; hip and pelvic fractures in women and older adults; low blood pressure and fainting; appendicitis; kidney stones; injection site reactions; taste disturbance
  • Low: Diabetic retinopathy complications; acute pancreatitis; thyroid C-cell tumors; pulmonary aspiration during anesthesia; depression and suicidal thoughts; serious hypersensitivity reactions; nutritional deficiencies
  • Speculative:

Monitoring

Marker Target Why
Body weight and waist circumference No established target; track percentage change from own baseline Primary efficacy marker
Lean mass (DXA) No established target; track lean-mass share of total weight lost Excessive lean loss
HbA1c 4.0–5.6% Expected to change
Fasting glucose 70–99 mg/dL Hypoglycemia with insulin or sulfonylureas
Blood pressure Below 130/80 mm Hg Expected to change; safety on blood-pressure medicines
Resting heart rate 60–100 beats per minute Label reports increases
Creatinine with eGFR Creatinine 0.59–1.04 mg/dL (women), 0.74–1.35 mg/dL (men) Dehydration-related acute kidney injury
hs-CRP No established target; track change from own baseline Expected to change
TSH (levothyroxine users on oral tablets) 0.4–4.0 mIU/L Oral semaglutide raises thyroxine exposure

Cadence: Baseline before starting; weight, side effects and glucose (if on insulin or sulfonylureas) every 4 weeks during dose escalation; labs at 3 months, then every 6–12 months; DXA every 6–12 months during active weight loss; kidney function promptly after severe vomiting or diarrhea

Qualitative Assessment

  • Appetite control and fewer intrusive thoughts about food
  • Gastrointestinal tolerance (nausea, constipation, reflux)
  • Energy, strength and exercise performance
  • Mood, cravings and alcohol intake
  • Vision changes, with sudden loss evaluated urgently
  • Hair shedding